Psychedelics for vets are ramping up in a big way.
The U.S. Department of Veterans Affairs (VA) is keeping a close eye on psychedelics research and policy, exploring issuing new guidance to protect veterans from losing their federal benefits over the use of substances like psilocybin.
VA is recruiting for future studies and actively hosting research projects on the substances on its campuses, and is funding and promoting studies into other “innovative treatments” like ketamine and cannabinoids. VA is also looking to update its guidance for clinicians to ensure that veterans can discuss their psychedelic use with their doctors without fear of losing their benefits.
The DEA is increasing its production quotas for psychedelics, and the NIMH is providing guidance for researchers on the types of studies it’s interested in funding for the development of psychedelic drugs to treat certain mental health conditions.